Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18903345 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | October 2024 | December 2024 | Allow | 2 | 1 | 0 | Yes | No |
| 18297081 | OPIOID RECEPTOR MODULATORS | April 2023 | September 2024 | Allow | 17 | 0 | 1 | No | No |
| 18164813 | RAS INHIBITORS | February 2023 | October 2024 | Allow | 21 | 0 | 0 | No | No |
| 18155343 | A METHOD FOR MANUFACTURING DEUTERATED BORON COMPOUND | January 2023 | June 2025 | Abandon | 29 | 2 | 0 | No | No |
| 18080744 | METHOD FOR SYNTHESIZING AN ANTI-CANCER COMPOUND THROUGH A ONE-POT REACTION | December 2022 | February 2025 | Abandon | 26 | 1 | 0 | No | No |
| 17982452 | ISOTOPICALLY ENRICHED ANALOGS OF 5,6-METHYLENEDIOXY-2-AMINOINDANE (MDAI) | November 2022 | March 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17875776 | GPR119 AGONISTS | July 2022 | June 2024 | Allow | 22 | 1 | 0 | No | No |
| 17639154 | P-GP INDUCERS AS PROTECTORS AGAINST CHEMOTHERAPY-INDUCED SIDE EFFECTS, SUCH AS PERIPHERAL NEUROPATHY (CIPN) AND HAIR LOSS | February 2022 | June 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17590603 | METHODS OF TREATING CANCER | February 2022 | June 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17629075 | 1,2-BIS(DIPHENYLPHOSPHINOALKYLAMIDO)-1,2-DISUBSTITUTED ETHANE, AND ITS SYNTHESIS AND APPLICATION | January 2022 | December 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17628659 | 7,8-DIHYDRO-4H-PYRAZOLO[4,3-c]AZEPINE-6-ONE COMPOUNDS | January 2022 | June 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17627275 | METHOD FOR OBTAINING AMORPHOUS REMIMAZOLAM BESYLATE | January 2022 | March 2025 | Allow | 38 | 1 | 0 | No | No |
| 17625487 | COMPOSITION COMPRISING O-CYCLIC PHYTOSPHINGOSINE-1-PHOSPHATE FOR PREVENTING OR TREATING PARKINSON'S DISEASE | January 2022 | March 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17624052 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17557008 | CAMPTOTHECIN-BASED DIMER COMPOUND, ANTICANCER DRUG AND METHOD OF ELIMINATING CANCER STEM CELL | December 2021 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17644187 | NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA | December 2021 | March 2025 | Allow | 39 | 1 | 0 | No | No |
| 17596151 | PYRROLOPYRIMIDINE COMPOUND AND USE THEREOF | December 2021 | April 2025 | Allow | 40 | 1 | 0 | No | No |
| 17596023 | NON-HYGROSCOPIC CRYSTALLINE SALTS OF A PYRAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | December 2021 | May 2025 | Allow | 42 | 1 | 0 | No | No |
| 17614240 | COMPOUND AND PRODUCTION METHOD THEREOF, AFX-TYPE ZEOLITE AND PRODUCTION METHOD THEREOF, AND HONEYCOMB STACKED CATALYST | November 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17613648 | BISAMINOQUINOLINES AND BISAMINOACRIDINES COMPOUNDS AND METHODS OF THEIR USE | November 2021 | March 2025 | Allow | 40 | 1 | 1 | No | No |
| 17529617 | SYNERGISTIC MIXTURES FOR FUNGAL CONTROLS IN CEREALS | November 2021 | October 2024 | Allow | 35 | 4 | 1 | Yes | No |
| 17607940 | MODULATORS OF TREX1 | November 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17513232 | IONIC CHANNEL MODULATION AS A METHOD FOR TREATING TUMORS THROUGH INFLAMMASOME ACTIVATION | October 2021 | January 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17607325 | PIM KINASE INHIBITOR COMPOSITIONS AND USES THEREOF | October 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17606827 | POLYMORPHS OF 7-CYCLOPENTYL-N,N-DIMETHYL-2-{[5-(PIPERAZIN-1-YL) PYRIDIN-2-YL]-AMINO}-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR THE PREPARATION THEREOF | October 2021 | December 2024 | Allow | 38 | 1 | 0 | No | No |
| 17606658 | A GRK2 PROTEIN INHIBITOR COMPOUND AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | October 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17606154 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | October 2021 | March 2025 | Allow | 41 | 1 | 1 | No | No |
| 17606026 | COMBINATION THERAPEUTIC REGIMENS WITH 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL | October 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17604540 | MANUFACTURING PROCESS FOR AMIFAMPRIDINE PHOSPHATE | October 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17603550 | CD73 INHIBITORS | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17435262 | PROCESS FOR THE SYNTHESIS OF VORTIOXETINE | August 2021 | December 2024 | Allow | 40 | 0 | 1 | No | No |
| 17420389 | FLUORINE-CONTAINING SUBSTITUTED BENZOTHIOPHENE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | July 2021 | March 2025 | Allow | 44 | 2 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner RZECZYCKI, PHILLIP MATTHEW works in Art Unit 1625 and has examined 31 patent applications in our dataset. With an allowance rate of 54.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner RZECZYCKI, PHILLIP MATTHEW's allowance rate of 54.8% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RZECZYCKI, PHILLIP MATTHEW receive 0.94 office actions before reaching final disposition. This places the examiner in the 10% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by RZECZYCKI, PHILLIP MATTHEW is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +56.0% benefit to allowance rate for applications examined by RZECZYCKI, PHILLIP MATTHEW. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.